• The FDA has approved a new oral treatment, Sotyktu (deucravacitinib) for plaque psoriasis, a chronic skin condition.
• In clinical trials, the new drug was more effective than the current most popular oral drug for the condition, Otezla.
• The medication appears to be safe, though some questions linger.

By Robby Berman on September 10, 2022

Fact checked by Patricia Weiser, PharmD

read full article